60 Degrees Pharmaceuticals, Inc. (SXTP)
Market: NASD |
Currency: USD
Address: 1025 Connecticut Avenue NW
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
📈 60 Degrees Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.00
-
Upside/Downside from Analyst Target:
224.07%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
100-200%
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.200000 |
- |
2025-02-24 |
- |
Stock split |
|
Total Amount for 2025: $0.200000 |
| 2024 |
- |
$0.083333 |
- |
2024-08-12 |
- |
Stock split |
|
Total Amount for 2024: $0.083333 |
📅 Earnings & EPS History for 60 Degrees Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2025-05-15 | -1.56 |
| 2025-03-27 | -14.2 |
| 2024-11-14 | -0.93 |
| 2024-08-14 | -4.23 |
| 2024-08-13 | -4.23 |
| 2024-05-15 | 0.03 |
| 2024-05-14 | 0.03 |
| 2024-04-01 | -0.36 |
| 2024-03-31 | -0.36 |
| 2023-11-20 | 0.77 |
| 2023-11-19 | 0.77 |
📰 Related News & Research
No related articles found for "60 degrees".
